Patent application number | Description | Published |
20090251344 | Successive Approximation Analog To Digital Converter - A system and method are provided allowing for successive approximation analog to digital conversion. A first differential voltage is sampled and held during a first cycle. The first differential voltage is converted to a differential current. A second differential voltage is generated based on the differential current flowing through parallel-coupled respective first and second variable resistances. First and second portions of the second differential voltage are compared to produce a comparison result therefrom. Successive approximation is used to generate a signal based on the comparison result, the signal being an output signal and being used to control resistances of respective ones of the first and second variable resistances during subsequent cycles. | 10-08-2009 |
20100259300 | Circuit for digitally controlling line driver current - In one embodiment, a circuit for providing a tail current for a line driver includes an adjustable current source. The adjustable current source includes a number of current source cells coupled together in a parallel configuration, where the current source cells are configured to provide the tail current for the line driver in response to a digital control signal. The circuit can further include a digital core coupled to the adjustable current source, where the digital core provides the digital control signal. The digital control signal provides a number of bits, where each bit controls one of the current source cells. In one embodiment, a current source cell can comprise a number of current source sub-cells. The current source cells can be configured to provide the tail current for the line driver in response to the digital control signal when the line driver is operating in a class AB mode. | 10-14-2010 |
20100259340 | Active termination and switchable passive termination circuits - According to one exemplary embodiment, an active termination circuit includes at least one active termination branch, where the at least one active termination branch includes at least one transistor for providing an active termination output. The at least one active termination branch further includes an amplifier driving the at least one transistor, where the amplifier has a non-inverting input coupled to the active termination output via a feedback network. The amplifier controls a current flowing through the at least one transistor so as to provide the active termination output. The active termination output can be provided at a drain of the at least one transistor, where a source of the at least one transistor is coupled to ground through a degeneration transistor and a tail current sink. | 10-14-2010 |
20110204967 | False-link protection circuit and method for utilizing same - Disclosed is a false-link protection circuit comprising at least one native switch coupled between a communication terminal of a first differential switch and a communication terminal of a second differential switch. The at least one native switch is configured to provide an attenuation path for a pulse link signal received by either communication terminal when the first and second differential switches are in a powered down state. According to one embodiment, a method to attenuate a pulse link signal comprises activating a native switch of a false-link protection circuit by powering down first and second differential switches, receiving a pulse link signal at a communication terminal of one of the first and second differential switches, and attenuating the pulse link signal by diverting it through the false-link protection circuit when the first and second differential switches are in a powered down state. | 08-25-2011 |
20110254584 | Switchable Passive Termination Circuits - According to one exemplary embodiment, an active termination circuit includes at least one active termination branch, where the at least one active termination branch includes at least one transistor for providing an active termination output. The at least one active termination branch further includes an amplifier driving the at least one transistor, where the amplifier has a non-inverting input coupled to the active termination output via a feedback network. The amplifier controls a current flowing through the at least one transistor so as to provide the active termination output. The active termination output can be provided at a drain of the at least one transistor, where a source of the at least one transistor is coupled to ground through a degeneration transistor and a tail current sink. | 10-20-2011 |
20130106629 | MULTI-BIT SUCCESSIVE APPROXIMATION ADC | 05-02-2013 |
20130120176 | RESISTIVE DIGITAL-TO-ANALOG CONVERSION - Examples of resistive digital-to-analog converter (RDAC) circuits are provided herein. RDAC circuits may provide an analog output signal derived from an n-bit digital input signal. In one example, an RDAC circuit may include a plurality of resistive circuit branches. Each resistive circuit branch may be arranged in a pull up/pull down network configuration. For example, an RDAC circuit may include a plurality of resistive circuit branches positioned in parallel. In an example, each of the plurality of resistive circuit branches may include a first inverter circuit, a second inverter circuit, and a resistive component. The RDAC circuit may include an output node for providing the analog output signal. Additionally, methods are provided for converting an analog output signal derived from an n-bit digital input signal. | 05-16-2013 |
20130201043 | SERIAL-RIPPLE ANALOG-TO-DIGITAL CONVERSION - Examples are provided for converting an analog signal to a digital output signal using serial-ripple analog-to-digital conversion (ADC). An ADC circuit may include conversion stages coupled in series. Each conversion stage may generate a bit for the digital output signal. A data latch may receive bits for the digital output signal from the conversion stages and to provide the digital output signal based on the bits. A conversion stage may include a comparator circuit and a multiplexer circuit. The comparator circuit may compare a sampled input signal with a reference signal and to generate the associated bit of the digital output signal based on a result of the comparison. The multiplexer circuit may provide an associated reference signal to a comparator circuit of a next conversion stage, where the next conversion stage is subsequent to the conversion stage. | 08-08-2013 |
20140133524 | HYBRID RESISTIVE DIGITAL-TO-ANALOG DEVICES - A differential resistor-based digital-to-analog converter (RDAC) can include a positive digital-to-analog converter (PDAC) stage and a negative digital-to-analog converter (NDAC) stage. A first network of resistors of the PDAC stage can be electrically coupled to a second network of resistors of the NDAC stage utilizing an intermediary network of resistors. Further, a differential receiver can include a first input and a second input. The first input can be electrically coupled to a first resistor of the intermediary network of resistors, and the second input can be electrically coupled to a second resistor of the intermediary network of resistors. Furthermore, a portion of the first network of resistors can be electrically coupled to a positive output of the RDAC, and another portion of the second network of resistors can be electrically coupled to a negative output of the RDAC. | 05-15-2014 |
Patent application number | Description | Published |
20110295225 | METHOD FOR THE PREPARATION OF A HIGH-TEMPERATURE STABLE OXYGEN-CARRIER-CONTAINING PHARMACEUTICAL COMPOSITION AND THE USE THEREOF - A high temperature-stable and highly purified α-α cross-linked tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. The dimeric form of hemoglobin is degenerated and purification processes are performed on red blood cells obtained from whole blood. Controlled hypotonic lysis in an instant cytolysis apparatus prevents the lysis of white blood cells. Nucleic acids from white blood cells and the phospholipids impurities are not detected. The blocking of reactive sulfhydryl groups in hemoglobin by a sulfhydryl reagent is performed in an oxygenated environment. Flowthrough column chromatography is used to remove different plasma protein impurities. N-acetyl cysteine is added to the α-α cross-linked tetrameric hemoglobin solution to maintain a low level of met-hemoglobin. The stabilized hemoglobin is preserved in an infusion bag with aluminum overwrap to prevent formation of inactive met-hemoglobin from oxygen intrusion. The product finds use in tissue oxygenation and cancer treatment. | 12-01-2011 |
20110319332 | TREATMENT METHODS USING A HEAT STABLE OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITION - A highly purified and heat stable cross-linked nonpolymeric tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin, uncross-linked tetrameric hemoglobin, and plasma protein impurities effectively. Addition of N-acetyl cysteine after heat treatment and optionally before heat treatment maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. The inventive tetrameric hemoglobin can also be used to prevent tumor metastasis and recurrence following surgical tumor excision. Further the inventive tetrameric hemoglobin can be administered to patients prior to chemotherapy and radiation treatment. | 12-29-2011 |
20110319858 | METHOD FOR THE PREPARATION OF A HEAT STABLE OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF - A highly purified and heat stable α-α cross-linked tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin and the plasma proteins impurities effectively. Addition of N-acetyl cysteine to the heat stable a-a cross-linked tetrameric hemoglobin maintains a low level of met-hemoglobin. The heat stable a-a cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. Another application is heart preservation in situations where there is a lack of oxygen supply in vivo, such as in heart transplant or oxygen-deprived heart. | 12-29-2011 |
20130059000 | ORAL DELIVERY FOR HEMOGLOBIN BASED OXYGEN CARRIERS - A process for making hemoglobin based oxygen carrier (HBOC) containing pharmaceutical composition suitable for oral delivery and the composition formed thereby are described. There are three exemplary composition configurations which include (1) hemoglobin-loaded nanoparticles solution, (2) enteric-coated hemoglobin capsules and (3) enteric-coated hemoglobin tablets. To facilitate the bioavailability and bio-compatibility of hemoglobin, intestinal absorption enhancers are added in each of the HBOC formulations. Protective layers ensure delivery of an intact hemoglobin structure in intestinal tract without degradation in the stomach. The HBOC formulations may be used for preventive or immediate treatment of high altitude syndrome (HAS) or for treatment of hypoxic conditions including blood loss, anemia, hypoxic cancerous tissue, and other oxygen-deprivation disorders. In addition to delivering oxygen, the heme group of hemoglobin from HBOC formulations can provide heme iron to the human body to aid in the production of more red blood cells. | 03-07-2013 |
20130219829 | METHOD FOR THE PREPARATION OF A HEAT STABLE OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITION AND THE USE THEREOF - A highly purified and heat stable cross-linked tetrameric hemoglobin suitable for use in mammals without causing renal injury and vasoconstriction is provided. A high temperature and short time (HTST) heat processing step is performed to remove undesired dimeric form of hemoglobin and the plasma proteins impurities effectively. Addition of N-acetyl cysteine to the heat stable cross-linked tetrameric hemoglobin maintains a low level of met-hemoglobin. The heat stable cross-linked tetrameric hemoglobin can improve and prolong oxygenation in normal and hypoxic tissue. In another aspect, the product is used in the treatment of various types of cancer such as leukemia, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal carcinoma and esophageal cancer. Another application is heart preservation in situations where there is a lack of oxygen supply in vivo, such as in heart transplant or oxygen-deprived heart. The presently claimed invention also includes a method for preparing a packaged cross-linked tetrameric hemoglobin composition. | 08-29-2013 |
20140106004 | HEMOGLOBIN-BASED OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITION FOR CANCER TARGETING TREATMENT AND PREVENTION OF CANCER RECURRENCE - The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1α, VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor. | 04-17-2014 |
20140255377 | PHARMACEUTICAL COMPOSITION COMPRISING ALBUMIN-BINDING ARGININE DEIMINASE FOR CANCER TARGETING TREATMENT - The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fusion protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases. The composition can be used alone or in combination with at least one chemotherapeutic agent to give a synergistic effect on cancer treatment and/or inhibiting metastasis. | 09-11-2014 |
20140303085 | HEMOGLOBIN-BASED OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITION FOR CANCER TARGETING TREATMENT AND PREVENTION OF CANCER RECURRENCE - The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1 α, VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor. | 10-09-2014 |
20140335018 | PHARMACEUTICAL COMPOSITION COMPRISING MODIFIED HEMOGLOBIN-BASED THERAPEUTIC AGENT FOR CANCER TARGETING TREATMENT AND DIAGNOSTIC IMAGING - The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging. | 11-13-2014 |
Patent application number | Description | Published |
20100130915 | APPLICATION OF VACUUM AS A METHOD AND MECHANISM FOR CONTROLLING EYE CHAMBER STABILITY - A phacoemulsification system for operating a surgical handpiece having a handpiece; an irrigation fluid source for supplying irrigation fluid to the eye; an aspiration source coupled to the handpiece in order to aspirate the irrigation fluid from the eye through the handpiece; and a controller for controlling a vacuum in the handpiece, the controller comprising: a sensor for sensing the vacuum in the handpiece; an occlusion parameter, the occlusion parameter being a vacuum level corresponding to an occlusion of the handpiece or a flow rate corresponding to an occlusion of the handpiece; a maximum allowable vacuum level in the handpiece, the maximum allowable vacuum level having at least a first predetermined level; and a trigger value that is set based in part on the occlusion parameter. | 05-27-2010 |
20100280434 | AUTOMATICALLY PULSING DIFFERENT ASPIRATION LEVELS TO AN OCULAR PROBE - Methods and systems for automatically pulsing different aspiration levels to an ocular probe are disclosed. The probe may be a phacoemulsification probe. A first aspiration level, supplied by a first pump, may be applied to the probe simultaneously with ultrasonic energy. A second aspiration level, supplied by a second pump, may be automatically switched from the first aspiration level, and applied to the probe in a pulsed manner. | 11-04-2010 |
20100280435 | AUTOMATICALLY SWITCHING DIFFERENT ASPIRATION LEVELS AND/OR PUMPS TO AN OCULAR PROBE - Methods and apparatuses for automatically switching different aspiration levels to an ocular probe are disclosed herein. The probe may be a phacoemulsification probe. A first aspiration level, supplied by a first pump, may be applied to the probe simultaneously with ultrasonic energy. A second aspiration level, supplied by a second pump, may be automatically switched from the first aspiration level. Control feed back of the pumps may be varied according to set thresholds. | 11-04-2010 |
20110087156 | APPLICATION OF A SYSTEM PARAMETER AS A METHOD AND MECHANISM FOR CONTROLLING EYE CHAMBER STABILITY - A controller for a phacoemulsification system having a handpiece; an irrigation fluid source configured to supply an irrigation fluid to the eye; an aspiration source configured to aspirate the irrigation fluid from the eye through the handpiece; and a controller comprising a duration timer configured to provide a duration of an occlusion, the controller configured to: sense a value of an occlusion indicating parameter corresponding to an occlusion of the handpiece; measure a time since the occlusion of the handpiece; and control the aspiration source to the handpiece based at least in part on the measured time since the occlusion. The occlusion indicating_parameter may be a vacuum level, an irrigation flow rate, and/or an aspiration flow rate. | 04-14-2011 |
20110092887 | METHOD FOR PROGRAMMING FOOT PEDAL SETTINGS AND CONTROLLING PERFORMANCE THROUGH FOOT PEDAL VARIATION - The present invention pertains to programming a foot pedal and switches located therewith that is used with a medical device and/or medical device system. A user may select any switch or directional movement available on the foot pedal for programming by activating the switch and/or moving a treadle located on the foot pedal or by selecting a foot pedal feature on a display. The programming options available for the selected switch or directional movement are displayed on the display screen. Using the foot pedal, the display screen, voice command or combinations thereof, the user can navigate through different options to select one or more options and confirm the chosen option(s) for the particular switch or directional movement. The control and feel of the movement of the treadle and/or switch provides the user with the ability to program custom settings that suit the user's foot position(s) and/or particular style of surgery. | 04-21-2011 |
20130072853 | SYSTEMS AND METHODS FOR CONTROLLING VACUUM WITHIN PHACOEMULSIFICATION SYSTEMS - The invention relates to systems and methods for controlling vacuum within phacoemulsification systems. The phacoemulsification system may include a handpiece having a needle. The needle is coupled to a power source configured to cause the needle to be ultrasonically vibrated during operation and an aspiration source. The system further includes a footpedal that defines a first position and a second position. The system also includes a computer program product operatively coupled to the handpiece and the footpedal, the computer program product having a computer-usable medium having a sequence of instructions which, when executed by a processor, causes said processor to execute a process that controls power from the power source and vacuum from the aspiration source applied to the handpiece. The process includes the steps of providing a vacuum at a first level to the handpiece when the footpedal is at the first position; providing power to the handpiece when the footpedal is at the second position; and reducing the vacuum to a second level when the footpedal transitions from the first position to the second position. | 03-21-2013 |
20130123680 | FLUID MANAGEMENT SYSTEM FOR USE IN A MEDICAL PROCEDURE - An apparatus and method for controlling fluid flow provided by an apparatus to a patient's eye during a surgical procedure. The method includes automatically adjusting an irrigation fluid source to a predetermined height during the surgical procedure using the apparatus, receiving a request either that the irrigation fluid source be moved to a different height from the predetermined height or that a manual adjustment mode be entered, and ceasing automatic adjusting and requiring manual adjustment of the height of the irrigation fluid source until the surgical procedure is completed or an indication received to resume automatic height adjustment of the irrigation fluid source. As an alternative, fluid flow rate or intraocular pressure may be maintained, and the design may include making adjustments to default values in other modes based on the adjustment made. | 05-16-2013 |
20130131611 | MEDICAL DEVICE RECEPTACLE FILLING METHOD AND APPARATUS - An apparatus and method for dispersing fluid from a fluid dispersal line is provided. The method comprises initiating operation of the medical apparatus, determining whether fluid has been dispersed from the medical apparatus via the fluid dispersal line since said initiating occurred, and assessing whether fluid is available in the fluid dispersal line. If fluid has not been dispersed from the medical apparatus since said initiating occurred and fluid is not available in the fluid dispersal line, the method includes distributing a commanded quantity of fluid plus an amount of fluid determined to fill the fluid dispersal line. Otherwise the method disperses only the commanded quantity of fluid. | 05-23-2013 |
20140142493 | APPLICATION OF VACUUM AS A METHOD AND MECHANISM FOR CONTROLLING EYE CHAMBER STABILITY - A phacoemulsification system for operating a surgical handpiece having a handpiece; an irrigation fluid source for supplying irrigation fluid to the eye; an aspiration source coupled to the handpiece in order to aspirate the irrigation fluid from the eye through the handpiece; and a controller for controlling a vacuum in the handpiece, the controller comprising: a sensor for sensing the vacuum in the handpiece; an occlusion parameter, the occlusion parameter being a vacuum level corresponding to an occlusion of the handpiece or a flow rate corresponding to an occlusion of the handpiece; a maximum allowable vacuum level in the handpiece, the maximum allowable vacuum level having at least a first predetermined level; and a trigger value that is set based in part on the occlusion parameter. | 05-22-2014 |
20150073816 | COMPUTER-BASED OPERATING ROOM SUPPORT SYSTEM - A computer-based surgery support system and method for obtaining information of surgical procedures from networked equipment in an operating room, storing the retrieved information in a database, receiving a request for the stored information from a user terminal, and providing the stored information in accordance with the received request. The networked equipment may be configured for use in cataract surgical procedures, such as a phacoemulsification system. | 03-12-2015 |